Skip to main content
OpenTrials
Completed

NCT Number: NCT05418296

Assessing a Novel Virtual Environment That Assists With Activities of Daily Living

This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 110 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bruceville Point Senior Living Community, Elk Grove, California, United States

Loading trial locations.

About this study

Central themes in person-centered care are dignity/respect/choice for the care recipient.

This Phase l clinical study is a minimal risk study that focuses on how the new technology can support and amplify these principles, while assisting care staff.

The investigators will use a novel digital health device developed with user-centered design principles, mirroring a range of evidence-based non-pharmacological interventions for people living with Alzheimer's disease and its related dementias (AD/ADRD). This is a purpose-built virtual world depicting activities of daily living (ADLs). It contains interactive engagement stimuli, including customized digital artifacts that hold meaning to the person.

The investigators hypothesize that undertaking ADL-related virtual activities will support completions of actual ADLs, thereby increasing effectiveness and improving care outcomes.

Aim 1: Feasibility Successful outcomes are >55% participation rate and a statistically significant difference between assessments of participation and non-participation, indicating tolerability and acceptability of routine interventions.

Aim 2: Effectiveness

Successful outcomes are:

  • a reduction in ADL-related care challenges compared to baseline
  • reduced time spent on the evening ADLs compared to baseline
  • a reduction in negative response behaviors associated with the ADL
  • greater interest in the ADL
  • a positive shift in care staff attitudes

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The subject will have a diagnosis of AD/ADRD, or symptoms of an undiagnosed AD/ADRD as observed by professional care staff and confirmed by the head of clinical care. The investigators will neither include nor exclude participation based on cognitive test scores. The subject will have had challenge(s) completing one or more ADLs in the previous month, as discussed at staff meetings, referenced in care plans, or observed/experienced by direct care staff.

Other specifications:

  • Understand English or Russian.
  • Can sit comfortably for at least 15 minutes in a chair/wheelchair at a table or propped up in bed or princess chair with a tray table
  • Are not known to be in pain
  • Have good vision, or good corrected vision (i.e., glasses)
  • Have good hearing, or good corrected hearing (i.e., aids)
  • May sometimes have anxiety or agitation when undertaking ADLs.

Exclusion criteria

Ineligible subjects are those with significant non-AD/ADRD neurological, psychiatric, or physical impairment or those who are totally dependent upon others for ADLs.

Treatment and study plan

A novel digital health device

Device

A videogame-generated virtual world designed for the AD/ADRD care dyad.

Other names: DevaWorld

Primary outcomes

  1. Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL- Severe)

    Time frame: 6 weeks

    The ADCS-ADL assesses the competence of patients with Alzheimer's Disease (AD) in basic and instrumental activities of daily living (ADLs). It can be completed by a caregiver in questionnaire format, or administered by a clinician/researcher as a structured interview with a caregiver.

    There are 19 questions. The minimum and maximum values are 0 - 54. A higher score means a better outcome.

  2. The Neuropsychiatric Inventory - Nursing Home Version (NPI-NH) The Minimum and Maximum Values Are A Higher Score Means a Better or Worse Outcome.

    Time frame: 6 weeks

    The NPI-NH The NPI-NH has been used to characterize the psychopathology of patients in nursing homes as well as to measure the impact of anti dementia and psychotropic drugs and behavioral changes in dementia patients dwelling in nursing homes.

    There are questions. The minimum and maximum values are 12 - 120 A lower score means a better outcome.

Secondary outcomes

  1. Approaches to Dementia Questionnaire (ADQ)

    Time frame: 6 weeks

    The ADQ is a validated questionnaire that aims to assess participants' attitudes towards dementia, and has been shown to be reliable, easy to administer and to score. The ADQ is a 19-item survey that assesses attitudes towards people living with dementia using a five-point Likert scale ranging from 'strongly agree' to 'strongly disagree'.

    The total ADQ score ranges from 19 to 95, with higher scores reflecting more positive attitudes towards people living with dementia.

  2. Sense of Competence in Dementia Care Staff (SCIDS) Scale

    Time frame: 6 weeks

    The SCIDS scale provides a useful and user-friendly means of measuring sense of competence in care staff.

    There are questions. The minimum and maximum values are 17 - 68 A higher score means a better outcome.

  3. The Copenhagen Burnout Index

    Time frame: 6 weeks

    The Copenhagen Burnout Inventory (CBI) is a 19-item survey that measures burnout in three areas: personal, work-related, and client-related.

    Scale ranges from 0 to 300, with high scores indicating high levels of burnout. This inventory is self-administered

Sponsors and collaborators

Lead sponsor

mandy

Industry

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Assessing a Novel Virtual Environment That Primes Individuals Living With AD/ADRD to Accomplish Activities of Daily Living

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 14, 2022
Registry last updated
Feb 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.